Extracellular Vesicle Isolation via Anion Exchange Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing extracellular vesicles (EVs) with specific, reproducible properties are inefficient and not scalable, making it difficult to develop effective therapeutic approaches for conditions like brain inflammation and cognitive dysfunction following traumatic brain injury, as existing methods lack standardization and fail to consistently produce high-yield, clinically relevant EV preparations.
Innovation Solution
A method for enriching and isolating negatively charged extracellular vesicles (n-EVs) from mesenchymal stem cells, characterized by the absence of the CD9 surface epitope and the presence of CD63 and CD81, using a protein-free culture medium and anion exchange chromatography, which allows for scalable production and identification of EVs with defined properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If centrifugation is used for EV isolation, then EVs can be separated from culture medium, but the process is not easily scalable and has low efficiency for high-yield production
Solution Approach 1:
The patent extracts EVs from culture medium using a combination of filtration (0.22 μm filter) and ultracentrifugation (100,000 × g for 70 minutes), separating the target EVs from the complex culture medium while achieving high purity and scalability simultaneously
Solution Approach 2:
The patent employs a nested isolation strategy where EVs are first filtered from culture medium, then further purified through ultracentrifugation, creating a multi-stage nested process that achieves both high purity and high-yield scalable production
2Reliability
If current EV production methods are used, then EVs can be obtained, but they lack specifically identifiable and reproducible properties for pharmaceutical preparations
Solution Approach 1:
The patent changes key production parameters including using defined culture medium compositions, controlling cell density (500 cells/cm²), specifying incubation times (48-72 hours), and standardizing isolation conditions (centrifugation speed and duration) to ensure reproducible EV properties across batches
Solution Approach 2:
The patent establishes a universal standardized protocol that can be applied across different EV production scenarios, making the process easily manufacturable and scalable while maintaining consistent EV characteristics suitable for pharmaceutical applications
3Productivity
If EVs are produced without standardization, then production can proceed, but the EVs lack defined characteristics required for pharmaceutical preparations
Solution Approach 1:
The patent performs preliminary actions by pre-defining culture medium compositions, cell seeding densities, and isolation parameters before EV production begins, ensuring that both high productivity and precise manufacturing characteristics are achieved from the outset
Solution Approach 2:
The patent replaces non-standardized mechanical isolation methods with a standardized protocol combining filtration and ultracentrifugation under precisely controlled conditions, achieving both high-yield production and defined EV characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of EVs with consistent, reproducible properties, effectively reducing inflammation and improving cognitive function in animal models of traumatic brain injury by administering these EVs, demonstrating a significant reduction in pro-inflammatory cytokines and improvement in behavioral tests.
Implementation Method 1
The conditioned culture medium was applied to an anion exchange resin (Express Q; Whatman, Clifton, NJ) that had been equilibrated with 50 mM NaCl in 50 mM Tris buffer (pH 8.0). The resin was washed with 10 volumes of the equilibration buffer and then eluted with 25 volumes of 500 mM NaCl in 50 mM Tris buffer (pH 8.0).
Implementation Method 2
The medium was centrifuged at 2,565×g for 15 min to remove cells and debris, and the supernatant was applied directly at room temperature to a column containing the anion exchange resin
Data Source
AI summary
Preparations comprising an enriched population of extracellular vesicles (nEVs) having a negatively charged surface, and that are CD81+ and CD9−, are provided. Improved processes and methods for producing an enriched population of nEVs from non-murine cells, especially human origin cells and/or tissues, are disclosed. Therapeutic methods for using the preparations, including for reducing brain inflammation and treatment of various pathologies associated with brain inflammation, such as by intravenous or intranasal administration, are also described. Methods and preparations for reducing brain inflammation associated with traumatic brain injury (TBI) are also disclosed. A method for treating a patient having suffered a mild traumatic injury (mTMI), or concussion, such as a sports-related head injury, is also disclosed. The nEVs are also demonstrated to reduce the expression level of IL-Iβ in brain tissue of an animal having had traumatic brain injury. Methods for improving cognitive function and performance in animals after a traumatic brain injury is also demonstrated using the preparations of nEVs disclosed herein.